Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
Drug guidance

Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer

Condition

Breast

Cancer

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended datopotamab deruxtecan (Dato-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The decision was based on the unfavourable clinical and cost effectiveness of Dato-DXd compared with chemotherapy, at the price proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for datopotamab deruxtecan are provided in the Annex.

Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer (Published 16 Sep 2025)[PDF, 226 KB]

PES Datopotamab deruxtecan for previously treated HR-positive, HER2-negative advanced breast cancer (Published 16 Sep 2025)[PDF, 127 KB]

Back to top